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AngiogenesisDLC1 is a RhoGAP-containing tumor suppressor and many of DLC1's functions are absolutely dependent on its
RhoGAP activity. Through its RhoGAP domain, DLC1 inhibits the activity of RhoA GTPase, which regulates actin
cytoskeleton networks and dis/assembly of focal adhesions. Tensin1 (TNS1) is a focal adhesion molecule that
links the actin cytoskeleton to integrins and forms signaling complexes through its multiple binding domains.
Here, we report that TNS1 enhances RhoA activity in a DLC1-dependentmanner. This is accomplished by binding
to DLC1 through TNS1's C2, SH2, and PTB domains. Pointmutations at these three sites disrupt TNS1's interaction
with DLC1 aswell as its effect on RhoA activity. The biological relevance of this TNS1–DLC1–RhoA signaling axis is
investigated in TNS1 knockout (KO) cells and mice. Endothelial cells isolated from TNS1 KO mice or those
silenced with TNS1 siRNA show signiﬁcant reduction in proliferation, migration, and tube formation activities.
Concomitantly, the RhoA activity is down-regulated in TNS1 KO cells and this reduction is restored by further
silencing of DLC1. Furthermore, the angiogenic process is compromised in TNS1 KOmice. These studies demon-
strate that TNS1 binds to DLC1 and ﬁne-tunes its RhoGAP activity toward RhoA and that the TNS1–DLC1–RhoA
signaling axis is critical in regulating cellular functions that lead to angiogenesis.
© 2015 Elsevier B.V. All rights reserved.1. Introduction
Deleted in liver cancer 1 (DLC1, also known as ARHGAP7 and
STARD12 in human and p122RhoGAP in rat) was ﬁrst isolated from
rat brain as a phospholipase C delta 1 binding protein [1] and then
was independently cloned by subtractive hybridization as a gene homo-
zygously deleted in a human hepatocellular carcinoma [2]. Together
with its gene locus at human chromosome 8p22, a region frequently
deleted in liver cancer, DLC1 was considered as a potential tumor sup-
pressor in liver [3–5]. Further studies showed that DLC1 expression
was lost or down-regulated in various cancers including liver, breast,
lung, brain, stomach, colon, and prostate cancers due to either genomic
deletion or aberrant DNA methylation [3,4]. Mutations that altered the
expression or function of DLC1 were detected in pancreas [6], colon,
and prostate cancers [7]. These results suggest that DLC1 may function
as a tumor suppressor in tissues other than liver [3,4]. DLC1 contains a
SAM, a RhoGAP, and a START domain. Its RhoGAP domain suppresses
the activity of RhoA GTPase by converting the GTP-bound active RhoA
to GDP-bound inactive form. RhoA mediates cell adhesion, shape, and
migration through its roles in modulating actin cytoskeleton networksistry and Molecular Medicine,
I, Room 3210, Sacramento CAand focal adhesion turnover [8]. The essential role of the RhoGAP in
DLC1's tumor suppression and other activities is well established.With-
out a functional RhoGAP domain, DLC1 is not able to regulate cell shape,
proliferation, adhesion, and migration [4]. Therefore, tight control of its
RhoGAP activity is a critical task of DLC1.
Tensin is a focal adhesion family with four members: tensin1 (TNS1),
tensin2 (TNS2), tensin3 (TNS3), and C-terminal tensin-like (cten) [9].
TNS1 is the founding member of the family. It interacts with actin ﬁla-
ments and regulates actin polymerization [10]. Tensin contains a PTB
(phosphotyrosine binding) domain that binds to the NPXY motif in β-
integrin and a SH2 (Src homology 2) domain that binds to tyrosine phos-
phorylated proteins, including Axl, EGFR, Src, Fak, p130cas, and paxillin
[9,11–13]. TNS2 (160 kD) and TNS3 (180 kD) have very similar domain
structures and molecular masses with those of TNS1 (220 kD) [11,14,
15]. Cten, on the other hand, is a much smaller protein (80 kD) and
only shares the SH2 and PTB domains with other tensins [16]. Previously,
we have discovered that the SH2 domains of all tensins bind to DLC1 in a
phosphorylation-independent fashion and that this interaction is essen-
tial for recruiting DLC1 to focal adhesion sites and for DLC1's tumor sup-
pression activity [17]. However, the effect of this interaction on DLC1's
RhoGAP activity is not well understood.
In this report, we have established that TNS1 negatively regulates
DLC1's RhoGAP activity toward RhoA through its multiple interactions.
The biological signiﬁcance of this TNS1–DLC1–RhoA signaling axis is
demonstrated by showing abnormal cellular function and angiogenic
response in TNS1 knockout (KO) endothelial cells and mice.
Fig. 1. TNS1, TNS2, and TNS3, but not cten, regulate RhoA activity throughDLC1. (A) Cell lysates fromHEK293 transfectedwith indicated constructswere used to determine RhoA activities
by rhotekin pull down assays and shown as Rho-GTP levels. Whole cell lysates were immunoblotted (IB) with antibodies against RhoA or tomato (Tom) to show the expression levels of
endogenous RhoA and recombinant fusion proteins. (B) Bar graph shows quantiﬁcation of Rho-GTP level. Shown are means ± SD for a minimum of three repetitions per transfection
condition. TNS1, TNS2, and TNS3 signiﬁcantly reduced RhoGAP activity of DLC1when theywere individually compared to control (Tom). P value was calculated compared to Tom control
by Student's t-test. *, P b 0.05.
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2.1. Mice
TNS1 KO mice were produced by our group [18]. All animal proce-
dures were performed according to UC Davis guidelines for the care and
use of laboratory animals.2.2. Cell culture and reagents
HUVECswere cultured in endothelial cell growthmedium(ScienCell).
293T cells weremaintained in DMEM/high glucose with 10% fetal bovine
serum. Lipofectamine-2000 (Invitrogen)was used for transfections. TNS1
siRNA and DLC1 siRNA were purchased from Sigma-Aldrich.2.3. Plasmid constructions and mutagenesis
The full-length or truncated cDNA fragments encoding human TNS1
residues 75 to 310, 75 to 210, and 211 to 310 were subcloned in frame
into mammalian expression vector pTomato or pEGFP (Clontech). The
site-speciﬁc mutation of 244M (GD244AA), 252M (HK252AA), SH2M
(R1488A), and PTBM (FFRR1656AAAA) was introduced into TNS1
cDNA by site-directed mutagenesis. All constructs were veriﬁed by
DNA sequencing.2.4. Isolation of endothelial cells from mouse lung tissues
Lung tissues from three 7–10 day oldmicewere removed aseptically
and rinsed in ice-cold DMEM. After removal of the larger blood vessels,
Fig. 2. The N-terminal TNS1 binds to DLC1 through its C2 domain. (A) HEK293T cells transfected with indicated constructs were immunoprecipitated (IP) and then immunoblotted (IB)
with listed antibodies (upper panel). Whole cell lysates were analyzed for the expression of GFP fusion proteins (lower panel). (B) Sequence alignment of C2 domains in the human TNS1,
TNS2, TNS3 and PTEN. 244GD and 252HR are conserved (arrows) in all C2 domains. (C) Domain structures of TNS1 and DLC1 proteins are included.
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1.5 mg/ml collagenase A (Roche), at 37 °C for 45 min on a rotator. The
cellular digest was ﬁltered through sterile 70 μm nylon mesh and the
mesh washed with 15 ml 10% FBS–DMEM media to stop digestion.
Cells were centrifuged at 400 ×g for 10 min, resuspended in 0.1% BSA/
PBS, incubated with anti-CD31-antibody (BD) coated Dynabeads
(Invitrogen), and then separated in a magnetic ﬁeld. After washing
away of unbound cells, remaining cells were seeded on 2% gelatin
coated plates cultured with Endothelial cell medium (ScienCell). After
3–5 days, cells were separated again by anti-ICAM2 antibody (BD) coat-
ed Dynabeads. The cells were plated at a concentration of 300,000 cells/
ml into gelatin-coated T-25 ﬂasks, and subsequently split 1:2 at each
passage. After 3 passages, cells were immortalized using lentivirus
expressing SV40 large T antigen (Genecopoeia).2.5. RhoA activity assay
Cells were washed with ice-cold PBS and lysed. Equal protein
amounts of cell lysates were incubated with 30μg glutathione
S-transferase–Rho binding domain of rhotekin (GST-RBD) beads
(Cytoskeleton) for 1 h at 4 °C. The beads were then washed twice
with washing buffer and bound Rho proteins were analyzed by immu-
noblotting using an anti-RhoA antibody (Cell signaling).2.6. Migration assay
Cells (50,000 cells) were added to the upper chamber of a transwell
insert (Corning) with growth factor free media. Endothelial cell growth
medium (500 μL) was added to the lower chamber. After 6 h, cells were
ﬁxed and stained. Cells that had migrated to the bottom surface were
visualized microscopically and photographed.
2.7. In vitro tube formation assay
Growth factor-reducedMatrigel (BD Biosciences) was used to coat a
48-well plate (150 μL/well) and endothelial cells (50,000 cells/well)
were seeded with media (300 μL). After 4 h of incubation, capillary–
like structures were scored by measuring the lengths of tubules per
ﬁeld in each well at ×100 magniﬁcation with ImageJ software (NIH).
2.8. Aortic ring assay
Thoracic aortas from TNS1WT or KOmicewere dissected and trans-
ferred to ice-cold PBS. The fat tissuewas removed and 1-mm-long aortic
rings were sectioned and embedded in growth factor-reducedMatrigel.
Ringswere culturedwith 500 μL of conditionedmedia for 8 days and the
outgrowth of endothelial tubes was counted.
Fig. 3.TNS1 interactionwithDLC1 is essential for its regulation onDLC1's RhoGAP activity toward RhoA. (A) HEK293T cells co-transfectedGFP-DLC1with tomato vector (Tom), Tom-TNS1,
or Tom-TNS1mutants (C2M, SH2M, PTBM, or triple-mutant-C2+ SH2+ PTBM), were subjected to IP with anti-GFP and IBwith anti-tomato antibodies.(B) HEK293T cells co-transfected
GFP-DLC1with Tom, Tom-TNS1, or Tom-TNS1-triplemutantwere analyzed for RhoA activities. Bar graphs show quantiﬁcation of binding ability (left) or Rho-GTP level (right). Shown are
means ± SD for a minimum of three repetitions per transfection condition. P value was calculated compared to Tom control by Student's t-test. *, P b 0.05.
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Growth factor-reduced matrigel (250 μL, BD Biosciences) containing
60 U/ml heparin (Sigma-Aldrich) was subcutaneously injected into
the mice (8 weeks old). After 5 days, matrigel plugs were harvested and
embedded in OCT and frozen sections were processed for immunohisto-
chemical staining using CD31 antibody. CD31 expression levels were
scored by a blinded reviewer (AW) as 0 (no or low expression) or 1
(middle or high expression) per image. Scores from 8 non-overlapping
images per sectioned slide were added. Therefore the possible scores
were from 0 to 8. The ﬁnal results were the averages of a total of 8
non-continuous sectioned slides per plug sample and 8 plugs per group.3. Results
3.1. Tensins enhance RhoA activities only in the presence of DLC1
To examine whether tensins regulate DLC1 RhoGAP activity toward
its major target RhoA, we used HEK293T human kidney epithelial cells,which do not express endogenous TNS1 and DLC1, for assays (Fig. 1).
Overexpression of TNS1 as tomato-TNS1 (Tom-TNS1) fusion protein
alone in HEK293T showed no effect on the activity of RhoA as indicated
by the Rho-GTP level, whereas DLC1 (as GFP-DLC1) overexpression
alone decreased the level of Rho-GTP. Nonetheless, the reduction effect
of DLC1was abolished by co-expression of TNS1 and DLC1, demonstrat-
ing that TNS1 regulates RhoA activity in a DLC1-dependent fashion.
Other tensin members such as TNS2, TNS3, and cten were tested for
the similar function. Only expression of TNS2 or TNS3, but not cten,
enhanced RhoA activities in the presence of DLC1 (Fig. 1), suggesting
that a larger N-terminal fragment, which is not presented in cten, may
be required for suppressing DLC1's RhoGAP activity.
3.2. The C2 domain of TNS1 binds to DLC1
DLC1 binds to various tensinmembers at three separate regions: the
NTR (N-terminal region), SH2, and PTB domains. While our previous
studies had established the essential residues within SH2 and PTB
domains for their binding activities [17,19], the interaction between
TNS1-NTR and DLC1, and the critical residues in the NTR for DLC1-
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(aa 75–310) indeed interacted with the SAM domain in the N-
terminus of DLC1 by co-immunoprecipitation assays (Fig. 2Aa). Further
truncation analysis showed that the C-terminal region of TNS1-NTR
containing aa 211–310 (aka C2domain)was responsible for the binding
to DLC1-SAM (Fig. 2Ab). Since the SAMdomain of DLC1 is also known to
interact with the tumor suppressor PTEN within a region containing a
C2 domain [20], we analyzed the C2 regions of human TNS1, TNS2,
TNS3 and PTEN by sequence alignments (Fig. 2B). Several conserved
sites were identiﬁed as potentially critical residues involving DLC1-
SAM and C2 interaction. We mutated and tested two of them in TNS1:
244M (244GD to AA, also called C2 mutant) and 252M (252HK to AA).
As shown in Fig. 2Ac, while TNS1(211–310) and TNS1(211–310)252M
still interacted with DLC1-SAM, the binding was abolished in
TNS1(211–310)244M. A schematic diagram showing the domain
structure and mutation sites is shown in Fig. 2C.3.3. TNS1 triple-mutant is unable to bind to DLC1 and has no effect on
RhoA activity
To characterize each binding site in the context of full length pro-
teins, DLC1 was co-expressed with TNS1, TNS1-C2 mutant, TNS1-SH2
mutant, TNS1-PTB mutant, or TNS1 triple-mutant for binding assays
(Fig. 3A). The interaction of DLC1 to TNS1was reducedwith eachmuta-
tion and onlywhen all three sites (C2, SH2, and PTB)weremutated,was
the interaction totally disrupted. With this TNS1 triple-mutant, we in-
vestigated whether TNS1's effect on RhoA activity required its physical
interaction with DLC1. As shown in Fig. 3B, lacking DLC1–TNS1 interac-
tion, TNS1 triple-mutant has no effect on RhoA activity, demonstrating
that binding of TNS1 to DLC1 negatively regulates its RhoGAP activity
toward RhoA.Fig. 4. Lack of TNS1 expression reduces the level of active RhoA, which could be restored by fur
isolated fromWT or TNS1 KOmicewere lysed for RhoA activity assays (left panel). TNS1 KO ce
panel). (B) HUVEC transfected with control (siCont), TNS1 siRNA (siTNS1), or siTNS1 togethe
immunoblotted with TNS1, DLC1, and RhoA antibodies to assess TNS1 or DLC1 depletion in ce
of Rho-GTP. Shown aremeans± SD for aminimum of three repetitions per transfection conditi3.4. Tensin1–DLC1–RhoA signaling axis is critical for cellular functions in
endothelial cells and angiogenesis in mice
To investigate the TNS1–DLC1–RhoA signaling axis in endothelial
cells and its biological signiﬁcance,we isolated and analyzed endothelial
cells from TNS1 KO or WT mouse lung tissues. As predicted, the
Rho-GTP level was markedly reduced in TNS1 KO endothelial cells
(Fig. 4A). The Rho-GTP reduction was restored by further silencing of
DLC1 in TNS1 KO cells (Fig. 4A). These results were reproducible in
human umbilical vascular endothelial cells (HUVEC). Silencing of TNS1
in HUVEC suppressed the Rho-GTP level and further knockdown of
DLC1 restored RhoA activity (Fig. 4B). Functional analysis of these cells
showed that lack of TNS1 reduced endothelial cell proliferation
(Fig. 5A), migration (Fig. 5B), and tube formation (Fig. 5C). Similar re-
sults were observed in human endothelial cells. Silencing of TNS1 in
HUVEC also led to decreased proliferation, migration, and tube forma-
tion (Fig. 5).
To examine the in vivo role of TNS1 in angiogenesis,matrigel plug as-
says were performed in TNS1 KO andWTmice. Five days post-injection,
gel plugs were isolated and stained for CD31 positive blood vessels.
Matrigel implanted in TNS1 KO mice consistently induced fewer vessel
formation (Fig. 6A). In ex vivo aortic spouting assays, aortic rings isolated
from TNS1 KO also grew signiﬁcantly less angiogenic vessels (Fig. 6B).
Together with results from analyzing endothelial cells, our studies
have suggested that TNS1 mediates angiogenic response likely through
the TNS1–DLC1–RhoA pathway in endothelial cells.4. Discussion
Our studies have established a novel function of TNS1, TNS2, and
TNS3, but not cten, in promoting RhoA activity through its multi-ther silencing of DLC1 inmouse endothelial cells. (A) Primary endothelial cells (mEndoCs)
lls infected with either shGFP or shDLC1 lentivirus were analyzed for RhoA activities (right
r with siCont or siDLC1 were lysed to determine RhoA activities. Whole cell lysates were
lls and total RhoA levels were served as loading controls. Bar graph shows quantiﬁcation
on. P value was calculated by one-way ANOVAwith Tukey–Kramer post hoc test. *, P b 0.01.
Fig. 5. Loss of TNS1 reduces cell proliferation, migration, and tube formation. TNS1 WT, KO mouse endothelial cells or HUVEC transfected with siCont or siTNS1 were used for studies.
(A) The WST1 proliferation assay results of indicated cells from triplicate experiments. (B) Representative images of transwell cell migration of indicated cells and bar graphs of data
from triplicate experiments. (C) Representative images of tube formation of indicated cells. Arrow indicates the tube-like structure. Bar graphs of data from triplicate experiments,
means ± SD. P value was calculated by Student's t-test. *, P b 0.05.
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out to be complicated. It has been reported that the PTB of TNS2 [21],
SH2 of TNS1, TNS2, TNS3 and cten [17,22], and actin-binding domain
(ABD) at the NTR of TNS3 [23] are able to bindDLC1. Our current studies
have clariﬁed and establishedminimal mutations to abolish the binding
at each site. With the sequence similarity among tensins, it is very likely
that C2 regions of TNS1, TNS2, and TNS3, as well as the SH2 and PTB of
all tensins are able to interact with DLC1. Together with previous ﬁnd-
ing, tensin not only recruits DLC1 to focal adhesions [17,22] but also
modulates its RhoGAP activity. Disruption of the TNS1–DLC1–RhoA sig-
naling axis leads to the reduction of proliferation, migration, and tube
formation observed in TNS1 KO endothelial cells and angiogenic defects
in TNS1 KO mice.
DLC1's RhoGAP domain negatively regulates RhoA activity and is
essential for numerous functions including suppressing cell growth, ad-
hesion, and migration. Therefore it requires tight and ﬁne regulation incells. Our DLC1 mutation screening study has identiﬁed several mis-
sense and nonsense mutations in prostate and colon cancer samples
[7]. Missense mutations such as T301K and S308I, which are away
from the RhoGAP domain, resulted in reducing RhoGAP activity of
DLC1 and thereforeweakening its tumor suppression activity. This ﬁnd-
ing offers the ﬁrst clue that these sites or regions may be involved in al-
losteric regulation of DLC1's RhoGAP domain. However, T301K/S308I
mutations do not affect the interaction between DLC1 and TNS1
(unpublished data). It has then been suggested by Li's group that the
RhoGAP activity of DLC1 is inhibited by an intramolecular interaction
with its SAM domain [23]. The binding of TNS3 ABD to DLC1's SAM do-
main releases this inhibition, resulting in an increase in DLC1 RhoGAP
activity. This model is further polished by Lowy's lab with their discov-
ery that DLC1 is a target of CDK5 serine/threonine kinase [24], which
phosphorylates 4 serine sites (S120, S205, S422, and S509) in DLC1. In
the absence of phosphorylation, the N-terminal region of DLC1 binds
Fig. 6. Lack of TNS1 reduces in vivo and ex vivo angiogenesis. (A) Representative images of angiogenic response to Matrigel in TNS1WT and KO mice. Gel plugs from KO showed signif-
icantly lower CD31-positive vessels than WT samples. Arrows indicate CD31-positive vessels. Bar graph shows quantiﬁcation of vessel formation per sample. *P b 0.05.
(B) Representative images of aortic ring explants placed in Matrigel. Arrows indicate the tube-like structures. Bar graph shows quantiﬁcation of tube-like structure. Sprouting of aortic
explants from TNS1 KO is signiﬁcantly reduced. P value was calculated by Student's t-test. *, P b 0.05.
3264 Y.-P. Shih et al. / Biochimica et Biophysica Acta 1853 (2015) 3258–3265to its RhoGAPdomain and keeps it in a closed and inactive conﬁrmation.
Phosphorylation by CDK5 reduces the binding and places DLC1 in an
open conﬁrmation, allowing stronger interactionwith tensin and others
[24]. In addition to CDK5, Low's lab has recently shown that DLC1 is
phosphorylated byMEK/ERK on T301 and S308 sites and the phosphor-
ylation is critical for activation of its RhoGAP activity [25], which
supports our cancer mutation screening results mentioned above. Our
current ﬁnding has added a new spin on Li's model in that binding of
TNS1 (also TNS2 and TNS3) actually reduces the RhoGAP activity of
DLC1, instead of increases as in their report. This provides another
layer of ﬁne control on DLC1's RhoGAP activity. Although Lowy's report
indicates that depletion of TNS3 in multiple cell lines did not result in a
substantial change in Rho-GTP levels [24], when carefully examining
their Fig. S5 B & D, silencing of TNS3 did lead to Rho-GTP level reduction
in H1703, H157 and MCF10A, but not in A549, H358, and 293T [24].
Their Fig. S5B in fact had conﬁrmed that the former three lines were
DLC1-positive and later three were DLC1-negative cell lines. Their data
support our ﬁnding that tensin positively regulates RhoA activity in a
DLC1-dependent fashion.
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